Except for cytotoxic chemotherapy, targeting the EGFR is a milestone in targeted therapy for lung cancer, and the use of targeted agents has dramatically improved the survival and quality of life of patients with lung cancer; however, limited by acquired resistance, this targeted therapy is also unable to maintain long-term efficacy.106. This evidence concerns the gene EGFR and lung carcinoma.